Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 331.45M P/E - EPS this Y -45.50% Ern Qtrly Grth -
Income -42.49M Forward P/E -5.57 EPS next Y -4.20% 50D Avg Chg -12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.89 EPS next 5Y - 52W High Chg -54.00%
Recommedations 1.60 Quick Ratio 19.54 Shares Outstanding 137.59M 52W Low Chg 45.00%
Insider Own 13.44% ROA -17.66% Shares Float 102.85M Beta 0.60
Inst Own 62.88% ROE -25.74% Shares Shorted/Prior 1.62M/1.84M Price 2.62
Gross Margin - Profit Margin - Avg. Volume 590,404 Target Price 9.17
Oper. Margin - Earnings Date - Volume 286,608 Change -2.24%
About Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc. News
04/16/24 Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
04/12/24 Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
04/10/24 Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
04/09/24 Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
03/21/24 Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
02/29/24 Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
02/28/24 Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
01/05/24 Compass Therapeutics Provides Corporate Update
12/12/23 Compass Therapeutics Insider Ups Holding During Year
11/09/23 Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments
11/09/23 Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/07/23 Compass Therapeutics to Participate in Upcoming Investor Events
08/03/23 Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
06/22/23 Compass Therapeutics to be Added to the Russell 2000ยฎย and Russell 3000ยฎย Indexes
05/04/23 Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
04/26/23 Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
CMPX Chatroom

User Image brentkhack Posted - 1 day ago

$CMPX "random" 480k volume candle

User Image BioInTheHouse Posted - 2 days ago

$CMPX HC Wainwright analyst Joseph Pantginis reiterates Compass Therapeutics (CMPX) with a Buy and maintains $10 price target

User Image briefingcom Posted - 2 days ago

$CMPX: Compass Therapeutics announces that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240416080505CMPX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image DonCorleone77 Posted - 2 days ago

$CMPX Compass Therapeutics announces first patient dosed in Phase 1 study of CTX-8371 Compass Therapeutics announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors. "Dosing the first patient in the CTX-8371 Phase 1 represents the advancement of our third program into the clinic, which is an important milestone for the company," said Vered Bisker-Leib, PhD, Chief Executive Officer. "We recently published preclinical data in the peer-reviewed journal, OncoImmunology, supporting the novel mechanism of action of CTX-8371: proteolytic cleavage and subsequent loss of cell surface PD-1. We believe this mechanism drives the enhanced anti-tumor activity of CTX-8371 in preclinical models when compared to approved anti-PD-1 and PD-L1 therapies and warrants its evaluation in patients."

User Image Stock_Titan Posted - 2 days ago

$CMPX Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors https://www.stocktitan.net/news/CMPX/compass-therapeutics-announces-first-patient-dosed-in-the-phase-1-h95nrd0n58hu.html

User Image StockSurveyor69 Posted - 2 days ago

$CMPX is this stock ever gonna go up!?????

User Image Stock_Titan Posted - 6 days ago

$CMPX Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference https://www.stocktitan.net/news/CMPX/compass-therapeutics-announces-poster-presentations-at-the-nfwyj6tt3cef.html

User Image BigWaydog Posted - 1 week ago

$CMPX started buying back in today. Easy money here

User Image Stock_Titan Posted - 1 week ago

$CMPX Compass Therapeutics to Participate in the Stifel Targeted Oncology Days https://www.stocktitan.net/news/CMPX/compass-therapeutics-to-participate-in-the-stifel-targeted-oncology-u9t31rti4poe.html

User Image Stock_Titan Posted - 1 week ago

$CMPX Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting https://www.stocktitan.net/news/CMPX/compass-therapeutics-presents-data-demonstrating-elimination-of-mhc-gc4sebus4ksb.html

User Image StockSurveyor69 Posted - 1 week ago

$CMPX I thought this stock was supposed to be a winner ๐Ÿ˜” ๐Ÿ†

User Image JoeSpringer Posted - 2 weeks ago

$SAVA Whale's Private Biotech $KTRA Goes Public and Doubles, We Examine and Interview 10 am ET Stream Action: https://youtube.com/live/_ZNfiJjwtb0 $CMPX $IBB $XBI

User Image Stock_Titan Posted - 03/21/24

$CMPX Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/CMPX/compass-therapeutics-reports-2023-financial-results-and-provides-420sdjnx768e.html

User Image DailyStocksPicks Posted - 03/20/24

Today's Oversold Stock #5: Sutro Biopharma ($STRO): Sutro Biopharma's journey in developing groundbreaking cancer treatments is not without its market challenges. With its stock's recent dip and recovery, what lies ahead for STRO amidst the biotech sector's volatility? Uncover how clinical updates and investor sentiments shape its valuation. Is Sutro Biopharma truly oversold, or is it on the brink of a breakthrough? Gain insights into its potential in our in-depth analysis. $MESO, $AGEN, $CMPX, $FENC For Detailed $STRO Analysis Watch: https://youtu.be/Rp7HXX5q-1I

User Image Followsuit7 Posted - 1 month ago

$CMPX I was in this on its last rally and came out with a 200% banger when indices were basically selling off a few years ago. Back in at $1.51 and this time I'm not selling

User Image BigWaydog Posted - 1 month ago

$CMPX I ain't gonna lie I'm up pretty big on this little gem :)

User Image _www_larval_com_ Posted - 1 month ago

$CMPX 7%[18%] $STKS 6%[12%] $CXAI -5%[9%] $AJX 4%[-1%] $BGC -3%[-1%] most notable movement into the final minutes of trading.

User Image RobbyAxelrod1 Posted - 1 month ago

$CMPX Per last 10q we are good on cash till 2026 VERY!....

User Image BigWaydog Posted - 1 month ago

$CMPX picked up a few watchers :)

User Image RobbyAxelrod1 Posted - 1 month ago

$CMPX Anyone know the cash on hand?

User Image _www_larval_com_ Posted - 1 month ago

$UMAC -10%[7%] $APM -6%[-14%] $AIMD 5%[-14%] $CMPX -5%[2%] $UK 4%[14%] most notable movement into the final minutes of trading.

User Image TheStockWhale Posted - 1 month ago

$CMPX

User Image LifeSVR Posted - 1 month ago

$CMPX is this the day we break 2?

User Image Stock_Titan Posted - 02/29/24

$CMPX Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference https://www.stocktitan.net/news/CMPX/compass-therapeutics-to-participate-in-the-leerink-partners-global-22zp0r6brov9.html

User Image Stock_Titan Posted - 02/28/24

$CMPX Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial https://www.stocktitan.net/news/CMPX/compass-therapeutics-announces-publication-of-ctx-8371-preclinical-t63rbrgl78yy.html

User Image TheStockWhale Posted - 02/20/24

$CMPX #moonsoon

User Image BabyGangsterAX Posted - 2 months ago

$CMPX missed the bottom.. shix

User Image BigWaydog Posted - 2 months ago

$CMPX ๐Ÿš€๐Ÿš€๐Ÿš€

User Image ReactionAction Posted - 2 months ago

$CMPX filled $1.55

User Image redsstocktwits Posted - 2 months ago

$CMPX Wow we have 1 now in Phase 3 ๐Ÿ˜Ž I only have 6K shares that is why in am not monitoring this as much as i monitor my weed holdings... Hope this go to $50+/share after phase 3 so that i can recover some money that I MIGHT lose on my medmen $mmnff investment ๐Ÿ˜‚ For every pain there will be gain... GOOD LUCK TO US ALL https://www.compasstherapeutics.com/pipeline/

Analyst Ratings
HC Wainwright & Co. Buy Apr 16, 24
Wedbush Outperform Mar 22, 24
HC Wainwright & Co. Buy Mar 21, 24
HC Wainwright & Co. Buy Aug 3, 23
HC Wainwright & Co. Buy Mar 16, 23
Jefferies Buy Jan 31, 23
Stifel Buy Jan 27, 23
EF Hutton Buy Dec 16, 22
Raymond James Outperform Nov 10, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Mar 10 Buy 3.37 10,000 33,700 6,021,873 03/10/23
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 27 Buy 3.98 20,000 79,600 6,011,873 02/27/23
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Feb 15 Buy 3.86 20,000 77,200 5,991,873 02/15/23
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 31 Buy 4.05 20,000 81,000 5,471,873 01/31/23
Bisker-Leib Vered Chief Operating Offi.. Chief Operating Officer Nov 22 Sell 4.28 24,500 104,860 1,060,414 11/25/22
ORBIMED ADVISORS LLC Director Director Nov 08 Buy 3.21 402,000 1,290,420 15,219,994 11/10/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 28 Buy 2.32 10,000 23,200 5,431,873 09/28/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 26 Buy 2.27 15,000 34,050 5,421,873 09/27/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 07 Buy 3.03 15,000 45,450 5,406,873 09/08/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 01 Buy 2.83 15,000 42,450 5,391,873 09/01/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 10 Buy 2.64 15,000 39,600 5,361,873 08/10/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Aug 01 Buy 2.58 15,000 38,700 5,346,873 08/02/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 21 Buy 2.80 20,000 56,000 5,331,873 06/21/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 06 Buy 2.83 30,000 84,900 5,261,873 06/07/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jun 01 Buy 3.03 20,000 60,600 5,231,873 06/01/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 26 Buy 3.04 20,000 60,800 5,211,873 05/26/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 23 Buy 2.72 18,355 49,926 5,191,873 05/24/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 17 Buy 2.47 20,215 49,931 5,173,518 05/17/22
GORDON CARL L Director Director May 11 Buy 2.21 192,516 425,460 14,817,994 05/13/22
ORBIMED ADVISORS LLC Director Director May 11 Buy 2.21 192,516 425,460 14,817,994 05/13/22
ORBIMED ADVISORS LLC Director Director May 06 Buy 1.6 125,359 200,574 14,625,478 05/10/22
GORDON CARL L Director Director May 06 Buy 1.6 125,359 200,574 14,625,478 05/10/22
Schuetz Thomas J. CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER May 10 Buy 1.80 27,836 50,105 5,153,303 05/10/22
GORDON CARL L Director Director Nov 04 Buy 3.5 5,357,143 18,750,000 3,571,428 11/08/21
ORBIMED ADVISORS LLC Director Director Nov 04 Buy 3.5 5,357,143 18,750,000 3,571,428 11/08/21